Target Audience

Hematologists and Medical Oncologists, Hematology Residents and Fellows, and Members of the Allied Health Care team involved in the care of blood and marrow transplant patients.

Learning Objectives

At the end of this learning activity, learners will be able to:

• Identify patients eligible for CART therapy, appropriate bridging therapy and cellular therapy product selection
• Recognize and manage complications of cellular therapy
• Review the management of long-term complications of transplant and cellular therapy
• Review new therapies for GVHD
• Understand how to use NGS results for allogeneic transplant decisions

Accreditation Statement

McMaster University, Continuing Professional Development Program (CPD) is fully accredited by the Committee on Accreditation of Continuing Medical Education (CACME) to provide CFPC Mainpro+ and RCPSC Maintenance of Certification (MOC) study credits for Continuing Medical Education.

This activity is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada and approved by McMaster University Continuing Professional Development Program. You may claim a maximum of 6.5 MOC Section 1 hours (credits are automatically calculated).

Through an agreement between the Royal College of Physicians and Surgeons of Canada and the American Medical Association, physicians may convert Royal College MOC credits to AMA PRA Category 1 Credits™. Information on the process to convert Royal College MOC credit to AMA credit can be found at https://edhub.ama-assn.org/pages/about-ama-education.

Each attendee should only claim the hours they attended.